Novartis’ Femara Improves Disease-Free Survival In Breast Cancer Patients Post Tamoxifen – JCO Article
This article was originally published in The Pink Sheet Daily
Executive Summary
Cohort analysis demonstrates treatment with letrozole one to seven years after tamoxifen therapy led to 63 percent reduction in disease recurrence.